Vandetanib

The medication vandetanib is an inhibitor of the "tyrosine kinase" which is selectively targeted to RET proto oncogene, blocking VEGFR (Vascular Endothelial Growth Factor Receptor) and EGFR (Epidermal Growth Factor Receptor), preventing the progression and angiogenesis. Caprelsa is a kinase inhibitor indicated for symptomatic or progressive medullary thyroid cancer in patients 18 years of age or older, with unresectable locally advanced or metastatic disease. Caprelsa should not be used in patients with hypocalcemia, hypokalemia, hypomagnesemia, or congenital long QT syndrome. Hypocalcemia, hypokalemia, and/or hypomagnesemia must be corrected prior to Caprelsa administration and should be periodically monitored. The Risk Evaluation and Mitigation Strategy (REMS) program for Caprelsa is required by the FDA Off label indication; Non-Small Cell Lung Cancer ; Patient’s tumor is confirmed to have RET gene rearrangements <a id="